Adverse events of chemotherapy in tuberculosis with multidrug resistant mycobacteria
Author:
Open Access
- 30 March 2021
- journal article
- Published by In-Trend in Tuberculosis and socially significant diseases
- Vol. 9 (1) , 77-91
Abstract
The review presents current information on the prevalence of multidrug-resistant tuberculosis in the world and in Russia, analyzes the literature data on adverse events of its treatment, their frequency and types, methods of prediction and prevention.Keywords
This publication has 50 references indexed in Scilit:
- Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort StudyClinical Infectious Diseases, 2018
- Applicability of the shorter ‘Bangladesh regimen’ in high multidrug-resistant tuberculosis settingsInternational Journal of Infectious Diseases, 2017
- Peripheral neuropathy in persons with tuberculosisJournal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2016
- Multidrug-Resistant Tuberculosis and Culture Conversion with BedaquilineNew England Journal of Medicine, 2014
- Reacções adversas aos antibacilares em doentes internados: Gravidade e factores de riscoPulmonology, 2010
- Adverse reactions of anti‐tuberculosis drugs in hospitalized patients: incidence, severity and risk factorsPharmacoepidemiology and Drug Safety, 2007
- Glomerular nephrotoxicity of aminoglycosidesToxicology and Applied Pharmacology, 2007
- Risk Factors of Hepatotoxicity During Anti-tuberculosis TreatmentMedical Journal Armed Forces India, 2006
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981
- Toward the operational identification of adverse drug reactionsClinical Pharmacology & Therapeutics, 1977